Gal Care Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.12 M
as on 24-10-2024
- Company Age 16 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.80 Cr
as on 24-10-2024
- Satisfied Charges ₹ 5.00 M
as on 24-10-2024
- Revenue 29.22%
(FY 2023)
- Profit 38.30%
(FY 2023)
- Ebitda 34.65%
(FY 2023)
- Net Worth 24.25%
(FY 2023)
- Total Assets 41.66%
(FY 2023)
About Gal Care Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.12 M.
The company currently has active open charges totaling ₹1.80 Cr. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Deshabandhu and Anita serve as directors at the Company.
- CIN/LLPIN
U24232RJ2008PTC027365
- Company No.
027365
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Sep 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Gal Care Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deshabandhu  | Director | 12-Sep-2008 | Current |
| Anita | Director | 12-Sep-2008 | Current |
Financial Performance of Gal Care Pharmaceuticals.
Gal Care Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 29.22% increase. The company also saw a substantial improvement in profitability, with a 38.3% increase in profit. The company's net worth Soared by an impressive increase of 24.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gal Care Pharmaceuticals?
Unlock access to Gal Care Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Jun 2022 | ₹8.00 M | Open |
Others Creation Date: 23 Jun 2022 | ₹1.00 Cr | Open |
Kotak Mahindra Bank Limited Creation Date: 21 Mar 2014 | ₹5.00 M | Satisfied |
How Many Employees Work at Gal Care Pharmaceuticals?
Gal Care Pharmaceuticals has a workforce of 166 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gal Care Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gal Care Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
